Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene (Nasdaq: NGNE) announced inducement grants of non-qualified stock options to four new employees totaling 32,450 shares, approved March 2, 2026 and granted under the company's 2025 Inducement Plan.
The options carry an exercise price equal to Neurogene's closing stock price on the grant date and vest over four years: 25% after one year, then 1/48 monthly for three years, subject to continued employment.
Neurogene (Nasdaq: NGNE) announced the FDA granted Breakthrough Therapy designation for NGN-401 for Rett syndrome, based on interim Phase 1/2 data through Oct 30, 2025 showing clinically meaningful, durable, multidomain functional improvements.
NGN-401 is a one-time, intracerebroventricular gene therapy using EXACT transgene regulation; dosing in the Embolden registrational trial is expected to complete in Q2 2026. The program also holds RMAT and Rare Pediatric Disease designations and participated in FDA’s START Pilot Program.
Neurogene (Nasdaq: NGNE) management will participate in three investor conferences in February–March 2026: Guggenheim Emerging Outlook: Biotech Summit (Feb 12, 9:00 a.m. ET), TD Cowen 46th Annual Health Care Conference (Mar 4, 10:30 a.m. ET), and Leerink Global Healthcare Conference (Mar 9, 1:40 p.m. ET).
Each appearance includes a fireside chat and investor meetings. Live webcasts and limited-time replays will be available via the Investor Relations events page on Neurogene's website.
Neurogene (Nasdaq: NGNE) announced an inducement grant of non-qualified stock options totaling 2,820 shares to one new employee, approved by the Compensation Committee on February 2, 2026. The grant was made under the company’s 2025 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing stock price on the grant date and vest over four years: 25% at the first anniversary of vesting commencement, then monthly vesting of 1/48 thereafter, subject to continued employment.
Neurogene (NASDAQ: NGNE) provided a program update for NGN-401, a gene therapy for Rett syndrome, reporting that multiple participants were dosed in the Embolden registrational trial in Q4 2025 and that dosing completion is expected in Q2 2026. The company initiated 13 U.S. Embolden sites and reported positive interim Phase 1/2 data showing durable multidomain improvements across disease severity. Neurogene plans to present interim pediatric and adolescent/adult cohort results (pediatric n=8; adolescent/adult n=2) by mid-2026 with ≥12 months follow-up, is advancing early commercial-readiness and payor engagement, and expects cash runway through Q1 2028 while targeting a BLA submission as a key milestone.
Neurogene (Nasdaq: NGNE) announced management will participate in the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 with a company overview presentation and investor meetings starting at 7:30 a.m. PT.
A webcast of the presentation will be available from the company's Investor Relations website under events, and a replay will be accessible for a limited time.
Neurogene (Nasdaq: NGNE) announced that its Compensation Committee approved inducement grants of non-qualified stock options totaling 4,860 shares to two new employees, with a grant date of December 2, 2025.
The options were issued under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of NGNE common stock on the grant date. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date and 1/48 of the award each month thereafter, subject to continued employment.
Neurogene (Nasdaq: NGNE) reported third quarter 2025 results and program updates on November 14, 2025. The company reported $265.4 million in cash, cash equivalents and short-term investments as of September 30, 2025, which it says funds operations through the first quarter of 2028. Clinical updates highlighted updated interim Phase 1/2 pediatric data for NGN-401 in Rett syndrome showing multidomain, durable gains with an aggregate 35 developmental milestones/skills gained across 8 pediatric participants as of an October 30, 2025 cutoff.
Neurogene dosed the first participant in the Embolden registrational trial and has initiated 12 of 13 sites with complete enrollment expected in 3–6 months. Preclinical data presented support intracerebroventricular (ICV) delivery for broader brain biodistribution versus intrathecal lumbar (IT-L).
Neurogene (Nasdaq: NGNE) reported positive interim Phase 1/2 data for its NGN-401 gene therapy in the pediatric Rett syndrome cohort (data cutoff Oct 30, 2025). All 8 pediatric participants showed functional gains across core domains with an aggregate 35 developmental milestones/skills gained and durable, multidomain improvements observed up to 24 months post treatment. Safety (N=10) at the 1E15 vg dose was generally well-tolerated; treatment-related adverse events were Grade 1–2 and no HLH was observed. Additional clinical data is planned for 2026, and management will discuss results at the Stifel 2025 Healthcare Conference webcast on Nov 12, 2025 at 4:40 p.m. ET.
Neurogene (Nasdaq: NGNE) announced that the first participant was dosed in the Embolden registrational trial of NGN-401 for Rett syndrome on November 6, 2025. Embolden is a single-arm, open-label, baseline-controlled study evaluating a 1E15 vg intracerebroventricular dose in 20 females ages ≥3.
The company initiated 12 of 13 U.S. sites and expects to complete enrollment within three to six months. Management will present Phase 1/2 interim data at the Stifel 2025 Healthcare Conference on November 12, 2025, with a webcast and temporary replay available via investor relations.